PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Key buying criteria PART 06: Pipeline portfolio PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by application PART 09: Global diabetes drugs market • Introduction • Market overview • Market drivers • Market challenges • Market trends • Vendor analysis of global diabetes drugs market PART 10: Global testosterone replacement therapy market • Introduction • Market overview • Market drivers • Market challenges • Market trends • Vendor analysis of global testosterone replacement therapy market PART 11: Global human growth hormone market • Introduction • Market overview • Market drivers • Market challenges • Market trends • Vendor analysis of global human growth hormone market PART 12: Global thyroid hormone disorder drugs market • Market overview • Market drivers • Market challenges • Market trends • Vendor analysis of global thyroid disorder drugs market PART 13: Geographical segmentation • Global endocrinology drugs market by geographical segmentation 2015-2020 • Endocrinology drugs market in Americas • Endocrinology drugs market in EMEA • Endocrinology drugs market in APAC PART 14: Market drivers • Increase in prevalence of endocrine hormone-related diseases • Promising drug pipeline • Advances in drug delivery technology • Stringent regulatory conditions for biosimilar drugs PART 15: Impact of drivers PART 16: Market challenges • Generic erosion • Side effects and associated risks • Rising concerns in scientific community • Low diagnosis rate PART 17: Impact of drivers and challenges PART 18: Market trends • Development of drugs with novel mechanism and technologies • Strategic alliances and M&A • Increased awareness • Increase in outsourcing PART 19: Vendor landscape • Competitive scenario • Market share analysis 2015 • Novo Nordisk • Sanofi • Merck • Eli Lilly • AstraZeneca • AbbVie • Other prominent vendors PART 20: Appendix • List of abbreviations PART 21: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria for endocrinology drugs Exhibit 03: Pipeline portfolio: Global diabetes drugs market Exhibit 04: Pipeline portfolio: Global thyroid disorder drugs market Exhibit 05: Pipeline portfolio: Global human growth hormone drugs market Exhibit 06: Pipeline portfolio: Global testosterone drugs market Exhibit 07: Global endocrinology drugs market 2015-2020 ($ billions) Exhibit 08: Five forces analysis Exhibit 09: Market segmentation of global endocrinology drugs market by application Exhibit 10: Global endocrinology drugs market: YoY growth and revenue based on application 2015-2020 Exhibit 11: Global diabetes market by type of disease 2015 Exhibit 12: Top-selling diabetes drugs based on sales 2015 ($ billions) Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015 Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions) Exhibit 15: Market share analysis of vendors in global diabetes drugs market Exhibit 16: Global testosterone replacement therapy market 2015-2020 ($ billions) Exhibit 17: Global human growth hormone market 2015-2020 ($ billions) Exhibit 18: Global human growth hormone market 2015-2020 ($ billions) Exhibit 19: Segmentation of global endocrinology drugs market based on geography 2015 Exhibit 20: Global endocrinology drugs market revenue by geography 2015-2020 ($ billions) Exhibit 21: Global endocrinology drugs market by geography 2015-2020 Exhibit 22: Endocrinology drugs market in Americas 2015-2020 ($ billions) Exhibit 23: Endocrinology drugs market in EMEA 2015-2020 ($ billions) Exhibit 24: Endocrinology drugs market in APAC 2015-2020 ($ billions) Exhibit 25: Global endocrinology drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 26: Impact of drivers Exhibit 27: Impact of drivers and challenges Exhibit 28: Revenues from the sales of top seven products in type 2 diabetes market 2012-2014 ($ billions) Exhibit 29: Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($ billions) Exhibit 30: Exhibit 31: Novo Nordisk: Geographical segmentation of human insulins 2015 Exhibit 32: Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions) Exhibit 33: Geographical segmentation of Levemir 2015 Exhibit 34: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($ billions) Exhibit 35: Novo Nordisk: Revenue of NovoLog/NovoRapid by geography 2015 Exhibit 36: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($ billions) Exhibit 37: Novo Nordisk: Geographical split of revenues of NovoMix 2015 Exhibit 38: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions) Exhibit 39: Novo Nordisk: YoY revenue and growth rate of Victoza 2013-2015 ($ billions) Exhibit 40: Geographical segmentation of Victoza 2015 Exhibit 41: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and PrandiMet 2012-2014 ($ millions) Exhibit 42: Novo Nordisk: YoY growth rate and revenue of Norditropin 2013-2015 ($ billions) Exhibit 43: Novo Nordisk: Revenue of Norditropin by geography 2015 Exhibit 44: Novo Nordisk: Key takeaways Exhibit 45: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions) Exhibit 46: Sanofi: Geographical segmentation of Lantus by revenue 2015 Exhibit 47: Sanofi: YoY revenue and growth rate of Amaryl 2013-2015 ($ millions) Exhibit 48: Sanofi: Amaryl geographical segmentation by revenue 2015 Exhibit 49: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ million) Exhibit 50: Sanofi: Geographical segmentation of Toujeo by revenue 2015 (%) Exhibit 51: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions) Exhibit 52: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions) Exhibit 53: Sanofi: Key takeaways Exhibit 54: Merck: YoY revenue and growth rate of Januvia 2013-2015 ($ billions) Exhibit 55: Merck: YoY revenue and growth rate of Januvia 2013-2015 ($ billions) Exhibit 56: Merck: Key takeaways Exhibit 57: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions) Exhibit 58: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions) Exhibit 59: Eli Lilly: YoY revenue and growth rate of Trajenta and Jentadueto 2012-2015 ($ billions) Exhibit 60: Eli Lilly: YoY revenue of Trulicity 2014-2015 ($ millions) Exhibit 61: Eli Lilly: Trulicity geographical segmentation by revenue 2015 Exhibit 62: Eli Lilly: Key takeaways Exhibit 63: AstraZeneca: YoY revenue and growth rate of Farxiga 2013-2015 ($ millions) Exhibit 64: AstraZeneca: Geographical segmentation of Farxiga/Forxiga by revenue 2015 Exhibit 65: AstraZeneca: YoY revenue and growth rate of Byetta 2013-2015 ($ million) Exhibit 66: AstraZeneca: YoY revenue and growth rate of Bydureon 2013-2015 ($ millions) Exhibit 67: AstraZeneca: YoY revenue and growth rate of Kombiglyze/Komboglyze/Onglyza 2013-2015 ($ millions) Exhibit 68: AstraZeneca: Key takeaways Exhibit 69: AbbVie: YoY revenue and growth rate of AndroGel 2013-2015 ($ millions) Exhibit 70: AbbVie: YoY revenue and growth rate of Synthroid 2013-2015 ($ millions) Exhibit 71: AbbVie: Key takeaways

AbbVie Inc., AstraZeneca PLC, Eli Lilly and Co., Merck & Co, Novo Nordisk AS, Sanofi SA, Acerus Pharmaceuticals, Acrux DDS, Adocia, Æterna Zentaris, Akros Pharma, Allergan, Amgen, Antares Pharma, Ascendis Pharma, Astellas Pharma, Baxalta, Bayer HealthCare Pharmaceuticals, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, ChipScreen Biosciences, Clarus Therapeutics, ConjuChem, Critical Pharmaceuticals, CureDm, CymaBay Therapeutics, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Endo Pharmaceuticals, Exsulin, Ferring Pharmaceuticals, Gan & Lee Pharmaceuticals, Genentech, Generex, Genexine, Genfit, GSK, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, ILTOO Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Ipe, Islet Sciences, Janssen Pharmaceuticals, Japan Tobacco, Juniper Pharmaceuticals, Kadmon Corporation, Kamada, KinDex Pharmaceuticals, Kissei Pharmaceutical, Kotobuki, Lexicon Pharmaceuticals, LG Life Sciences, Ligand Pharmaceuticals, Lipocine, Living Cell Technologies, MacroGenics, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, MetP Pharma, Mitsubishi Tanabe Pharma, Mylan, NGM Biopharmaceuticals, Novartis, NuSirt Biopharma, OPKO Biologics, Oramed Pharmaceuticals, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, ProStrakan Group, REGiMMUNE, Repros Therapeutics, Roche, Sanwa Kagaku Kenkyusho, Sirona Biochem, Strongbridge Biopharma, Takeda Pharmaceuticals, TesoRx Pharma, Teva Pharmaceutical, Theracos, Theratechnologies, Toleranzia, Tolerion, Transition Therapeutics, VeroScience, Versartis, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA.